Neumora Therapeutics, Inc. (NMRA) - Net Assets
Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has net assets worth $132.16 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($177.83 Million) and total liabilities ($45.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Neumora Therapeutics, Inc. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $132.16 Million |
| % of Total Assets | 74.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Neumora Therapeutics, Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore NMRA total asset value for the complete picture of this company's asset base.
Annual Net Assets for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual net assets of Neumora Therapeutics, Inc. from 2019 to 2024. For live valuation and market cap data, see Neumora Therapeutics, Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $287.06 Million | -38.80% |
| 2023-12-31 | $469.08 Million | +204.97% |
| 2022-12-31 | $-446.85 Million | -37.40% |
| 2021-12-31 | $-325.22 Million | -244.57% |
| 2020-12-31 | $-94.38 Million | -449347.62% |
| 2019-12-31 | $-21.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neumora Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 94720000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.00K | 0.01% |
| Other Comprehensive Income | $62.00K | 0.02% |
| Other Components | $1.23 Billion | 429.94% |
| Total Equity | $287.06 Million | 100.00% |
Neumora Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Plasson Indus
TA:PLSN
|
$414.68 Million |
|
Yang Guang Co Ltd
SHE:000608
|
$414.80 Million |
|
Pinlive Foods Co Ltd
SHE:300892
|
$414.85 Million |
|
HCM II Acquisition Corp
NASDAQ:HOND
|
$414.92 Million |
|
Eaton Vance Municipal Income Closed Fund
NYSE:EVN
|
$414.63 Million |
|
Taiwan Paiho Ltd
TW:9938
|
$414.46 Million |
|
Titan Machinery Inc
NASDAQ:TITN
|
$414.40 Million |
|
Guangdong Liantai Environmental Protection Co Ltd
SHG:603797
|
$414.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neumora Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 469,076,000 to 287,064,000, a change of -182,012,000 (-38.8%).
- Net loss of 243,787,000 reduced equity.
- New share issuances of 13,694,000 increased equity.
- Other comprehensive income increased equity by 138,000.
- Other factors increased equity by 47,943,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-243.79 Million | -84.92% |
| Share Issuances | $13.69 Million | +4.77% |
| Other Comprehensive Income | $138.00K | +0.05% |
| Other Changes | $47.94 Million | +16.7% |
| Total Change | $- | -38.80% |
Book Value vs Market Value Analysis
This analysis compares Neumora Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $2.44 | x |
| 2020-12-31 | $-0.62 | $2.44 | x |
| 2021-12-31 | $-2.14 | $2.44 | x |
| 2022-12-31 | $-2.94 | $2.44 | x |
| 2023-12-31 | $2.95 | $2.44 | x |
| 2024-12-31 | $1.80 | $2.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neumora Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -84.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-84.92%) is below the historical average (-27.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-89.83 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-204.79 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-86.22 Million |
| 2023 | -50.30% | 0.00% | 0.00x | 1.06x | $-282.83 Million |
| 2024 | -84.92% | 0.00% | 0.00x | 1.10x | $-272.49 Million |
Industry Comparison
This section compares Neumora Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | $132.16 Million | 0.00% | 0.35x | $414.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more